- Patent Title: Angiotensinogen (AGT) iRNA compositions and methods of use thereof
-
Application No.: US15313145Application Date: 2015-05-22
-
Publication No.: US10238749B2Publication Date: 2019-03-26
- Inventor: Donald Foster , Brian Bettencourt , Klaus Charisse , Gregory Hinkle , Satyanarayana Kuchimanchi , Martin Maier , Stuart Milstein
- Applicant: Alnylam Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Deborah L. Nagle
- International Application: PCT/US2015/032099 WO 20150522
- International Announcement: WO2015/179724 WO 20151126
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C07H21/02 ; C07H21/04 ; A61K47/54 ; C12N15/113 ; A61K45/06
Abstract:
The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
Public/Granted literature
- US20170189541A1 ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF Public/Granted day:2017-07-06
Information query
